Fully Attenuated meq and pp38 Double Gene Deletion Mutant Virus Confers Superior Immunological Protection against Highly Virulent Marek's Disease Virus Infection

• Published in: Microbiology spectrum 2022-12, Vol.10 (6), p.e0287122-e0287122
• Main Authors: Sun, Aijun, Zhao, Xuyang, Zhu, Xiaojing, Kong, Zhengjie, Liao, Yifei, Teng, Man, Yao, Yongxiu, Luo, Jun, Nair, Venugopal, Zhuang, Guoqing, Zhang, Gaiping
• Format: Article
• Language: English
• Subjects: Animals; Atrophy; Chickens; Gene Deletion; Herpesvirus 2, Gallid - genetics; lymphoid organ atrophy; Marek Disease - genetics; Marek Disease - prevention & control; Marek Disease Vaccines - genetics; Marek’s disease virus; meq; Oncogene Proteins, Viral - genetics; Poultry Diseases; pp38; Research Article; vaccine; Virology
• ISSN: 2165-0497; 2165-0497
• DOI: 10.1128/spectrum.02871-22

Marek's disease virus (MDV) induces immunosuppression and neoplastic disease in chickens. The virus is controllable via an attenuated deletion mutant virus, which has the disadvantage of retaining the ability to induce lymphoid organ atrophy. To overcome this deficiency and produce more vaccine candidates, a recombinant MDV was generated from the highly virulent Md5BAC strain, in which both and a cytolytic replication-related gene, , were deleted. Replication of the double deletion virus, Md5BAC Δ Δ , was comparable with that of the parental virus . The double deletion virus was shown to be fully attenuated and to reduce lymphoid organ atrophy . Crucially, Md5BAC Δ Δ confers superior protection against highly virulent virus compared with a commercial vaccine strain, CVI988/Rispens. Transcriptomic profiling indicated that Md5BAC Δ Δ induced a different host immune response from CVI988/Rispens. In summary, a novel, effective, and safe vaccine candidate for prevention and control of MD caused by highly virulent MDV is reported. MDV is a highly contagious immunosuppressive and neoplastic pathogen. The virus can be controlled through vaccination via an attenuated deletion mutant virus that retains the ability to induce lymphoid organ atrophy. In this study, we overcame the deficiency by generating and double deletion mutant virus. Indeed, the successfully generated and double deletion mutant virus had significantly reduced replication capacity but not . It was fully attenuated and conferred superior protection efficacy against very virulent MDV challenge. In addition, the possible immunological protective mechanism of the double deletion mutant virus was shown to be different from that of the gold standard MDV vaccine, CVI988/Rispens. Overall, we successfully generated an attenuated deletion mutant virus and widened the range of potential vaccine candidates. Importantly, this study provides for the first time the theoretical basis of vaccination induced by fully attenuated gene-deletion mutant virus.